Semaglutide Dosing Schedule and Amounts
For type 2 diabetes, start subcutaneous semaglutide at 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg once weekly, with optional escalation to 1 mg once weekly after at least 4 additional weeks if needed for glycemic control. 1
Subcutaneous Semaglutide Dosing
For Type 2 Diabetes (Ozempic)
The FDA-approved titration schedule is straightforward 1, 2:
- Initial dose: 0.25 mg subcutaneously once weekly × 4 weeks
- Maintenance dose: 0.5 mg once weekly after the initial 4-week period
- Maximum dose: 1 mg once weekly (increase only if additional glycemic control needed after ≥4 weeks at 0.5 mg)
Administration details:
- Inject once weekly on any day, at any time, with or without meals
- Injection sites: abdomen, thigh, or upper arm
- If a dose is missed, administer within 5 days of the missed dose
For Weight Management (Wegovy)
Higher doses are approved specifically for obesity treatment 3, 4:
- Subcutaneous semaglutide: Escalate to 2.4 mg once weekly for weight management
- Higher-dose option: 7.2 mg once weekly is now available for enhanced weight loss 3
The 2.4 mg dose demonstrated a mean weight reduction of -14.9% at 68 weeks, with 86.4% of participants achieving ≥5% weight loss 5. Research confirms that higher doses (2.0 mg or more weekly) provide additional benefits for both glycemic and weight management 6.
For Cardiovascular and Renal Protection
Subcutaneous semaglutide has regulatory approval for reducing MACE in adults with type 2 diabetes and established CVD, and for reducing CKD progression 3. The standard maintenance doses (0.5-1 mg weekly for diabetes indication) apply, though the cardiovascular benefits were demonstrated across the dose range.
Oral Semaglutide Dosing
For Type 2 Diabetes (Rybelsus)
Oral formulations require specific administration conditions due to ~1% bioavailability 7, 8:
- Take on an empty stomach with up to 120 mL (4 oz) of water
- Wait at least 30 minutes before eating, drinking, or taking other medications
- Overnight fasting until 30 minutes post-dose is required for adequate absorption 7
Dosing for diabetes: Typical maintenance doses are 7-14 mg daily 3
For Weight Management
Oral semaglutide 25 mg daily is approved for obesity treatment 3, 4:
- Provides comparable efficacy to subcutaneous 2.4 mg weekly
- Mean weight reduction of -13.6% at 64 weeks 9
- 82.2% of patients achieve exposure levels equivalent to subcutaneous 2.4 mg 10
Higher oral dose: 50 mg daily is available and demonstrated -15.1% body weight reduction at 68 weeks, matching subcutaneous efficacy 8
Key Clinical Considerations
Dose Titration in Real-World Practice
Important caveat: Real-world data shows significant deviation from approved titration schedules 11. In primary care settings:
- 40% of patients remain on ≤1.0 mg/week at 12 months
- Only 30% reach the 2.4 mg maintenance dose
- Despite slower titration, mean weight loss was still -13.6% in those who continued treatment
This suggests that while higher doses optimize outcomes, slower individualized titration may improve tolerability and persistence.
Gastrointestinal Tolerability
The gradual dose escalation is critical for minimizing GI adverse events 1, 5. Nausea, vomiting, and diarrhea are the most common side effects (occurring in ≥5% of patients), typically transient and mild-to-moderate. The 4-week intervals between dose increases allow GI adaptation.
Flexible Scheduling
There is no evidence that specific days of the week optimize outcomes 12. Administer on a consistent day that fits the patient's lifestyle to maximize adherence. If a dose is missed, it can be given within 5 days without disrupting the schedule 1.
Pregnancy Planning
Discontinue semaglutide at least 2 months before planned pregnancy due to the long washout period 1, 2.